Skip to main content
KOD
NASDAQ Life Sciences

Baker Bros. Adds $58.6M Kodiak Sciences Stake After Phase 3 Win

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$94.5
Mkt Cap
$5.958B
52W Low
$10.94
52W High
$98.8
52W Position info
764% above low
Off High info
4.4% below high
Rel. Volume info
3.4× avg
Market data snapshot near publication time

KOD has more than doubled off its 52-week low of $10.94 on elevated volume (3.4× avg).

Summary

Baker Bros. Advisors LP and affiliates purchased $58.6 million of Kodiak Sciences stock on the day the company reported positive Phase 3 results for two lead drug candidates.


Key Events · Ownership and Investor Activity · KOD

  • Baker Bros. Buys $58.6M of KOD

    Baker Bros. Advisors LP and affiliated funds acquired 807,840 shares for $58,625,708 on 2026-09-28 at prices ranging from $61.21 to $78.57.

  • Purchase Follows Positive Phase 3 Data

    The purchase occurred the same day Kodiak announced Zenkuda and tabirafusp-ted met primary endpoints in the DAYBREAK trial, driving the stock up sharply.

  • Stake Rises to 19.1M Shares

    Post-transaction holdings total 19,121,134 shares across the reporting entities, with Felix J. Baker serving as a director of the company.

  • Sophisticated Investor Confidence

    Baker Bros. is a prominent life-sciences investment firm with board representation; the size and timing of the purchase signal strong conviction in the company's clinical and commercial outlook.


Analysis · KOD · Life Sciences

A $58.6 million purchase of Kodiak Sciences stock by Baker Bros. Advisors LP and affiliated funds on September 28 underscores the significance of the company's Phase 3 results. That same day, Kodiak announced that both Zenkuda and tabirafusp-ted met primary endpoints in the pivotal DAYBREAK trial. The 807,840 shares were acquired at prices between $61.21 and $78.57, well above pre-announcement levels, bringing the group's total holdings to 19.1 million shares. This is a large, real-money commitment from a sophisticated life-sciences investor with board representation, made immediately after positive data — a strong vote of confidence in the company's commercial prospects.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KOD was trading at $94.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $10.94 to $98.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KOD - Latest Insights

KOD
Nov 12, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $108.12
Real-time Price: $103.62 info
Change: -$4.51 (-4%) info
Market Cap: $6.758B info
KOD
Nov 12, 2026, 4:00 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $108.25
Real-time Price: $103.62 info
Change: -$4.64 (-4%) info
Market Cap: $6.758B info
KOD
Nov 06, 2026, 4:55 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $99.30
Real-time Price: $103.62 info
Change: +$4.31 (+4%) info
Market Cap: $6.758B info
KOD
Oct 20, 2026, 5:19 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $92.97
Real-time Price: $103.62 info
Change: +$10.64 (+11%) info
Market Cap: $6.758B info
KOD
Sep 28, 2026, 8:53 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $60.69
Real-time Price: $103.62 info
Change: +$42.93 (+71%) info
Market Cap: $6.758B info